Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mammography | 81 | 2024 | 472 | 10.590 |
Why?
|
Breast Neoplasms | 69 | 2024 | 3011 | 5.590 |
Why?
|
Calcinosis | 38 | 2018 | 230 | 3.740 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 36 | 2017 | 469 | 3.520 |
Why?
|
Radiographic Image Enhancement | 38 | 2018 | 463 | 3.000 |
Why?
|
Diagnosis, Computer-Assisted | 30 | 2022 | 333 | 2.920 |
Why?
|
Algorithms | 34 | 2024 | 1877 | 2.310 |
Why?
|
Breast Diseases | 22 | 2017 | 100 | 2.240 |
Why?
|
Pattern Recognition, Automated | 12 | 2014 | 217 | 2.120 |
Why?
|
Breast | 11 | 2024 | 292 | 1.890 |
Why?
|
ROC Curve | 21 | 2024 | 781 | 1.330 |
Why?
|
Sensitivity and Specificity | 37 | 2018 | 2015 | 1.320 |
Why?
|
Early Detection of Cancer | 5 | 2024 | 416 | 1.310 |
Why?
|
Image Interpretation, Computer-Assisted | 8 | 2015 | 688 | 1.290 |
Why?
|
Mass Screening | 8 | 2023 | 636 | 1.160 |
Why?
|
Artificial Intelligence | 12 | 2023 | 322 | 1.090 |
Why?
|
Reproducibility of Results | 31 | 2017 | 2758 | 1.050 |
Why?
|
Image Processing, Computer-Assisted | 13 | 2018 | 1242 | 0.910 |
Why?
|
Female | 78 | 2024 | 46202 | 0.810 |
Why?
|
X-Ray Film | 4 | 2012 | 36 | 0.780 |
Why?
|
Models, Statistical | 5 | 2013 | 576 | 0.780 |
Why?
|
Precancerous Conditions | 6 | 2006 | 200 | 0.780 |
Why?
|
Imaging, Three-Dimensional | 8 | 2015 | 598 | 0.730 |
Why?
|
Models, Biological | 5 | 2013 | 1765 | 0.700 |
Why?
|
Humans | 104 | 2024 | 89357 | 0.680 |
Why?
|
Neoplasm Staging | 1 | 2024 | 2018 | 0.650 |
Why?
|
Breast Density | 2 | 2018 | 36 | 0.640 |
Why?
|
Diagnostic Imaging | 3 | 2024 | 479 | 0.530 |
Why?
|
Information Storage and Retrieval | 5 | 2012 | 121 | 0.520 |
Why?
|
Machine Learning | 1 | 2017 | 258 | 0.500 |
Why?
|
Registries | 3 | 2024 | 784 | 0.450 |
Why?
|
Technology Assessment, Biomedical | 1 | 2013 | 27 | 0.440 |
Why?
|
Chemokine CXCL1 | 1 | 2012 | 9 | 0.410 |
Why?
|
Preventive Health Services | 1 | 2011 | 39 | 0.390 |
Why?
|
X-Ray Intensifying Screens | 6 | 2012 | 32 | 0.380 |
Why?
|
Diagnostic Errors | 1 | 2012 | 160 | 0.370 |
Why?
|
Observer Variation | 9 | 2013 | 610 | 0.360 |
Why?
|
Computer Simulation | 6 | 2015 | 1097 | 0.350 |
Why?
|
Image Enhancement | 5 | 2016 | 567 | 0.340 |
Why?
|
Data Display | 1 | 2009 | 24 | 0.330 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2012 | 296 | 0.320 |
Why?
|
Carcinoma | 1 | 2012 | 443 | 0.310 |
Why?
|
Biophysics | 7 | 2002 | 153 | 0.280 |
Why?
|
Subtraction Technique | 3 | 2005 | 132 | 0.280 |
Why?
|
Radiologists | 2 | 2023 | 46 | 0.270 |
Why?
|
Task Performance and Analysis | 1 | 2006 | 87 | 0.270 |
Why?
|
Tomography, X-Ray Computed | 7 | 2017 | 2661 | 0.260 |
Why?
|
Artifacts | 3 | 2006 | 247 | 0.250 |
Why?
|
Ovarian Neoplasms | 1 | 2012 | 764 | 0.250 |
Why?
|
Pattern Recognition, Visual | 1 | 2006 | 155 | 0.250 |
Why?
|
Data Warehousing | 1 | 2024 | 4 | 0.240 |
Why?
|
Biomarkers, Tumor | 1 | 2012 | 1549 | 0.220 |
Why?
|
Medicine | 1 | 2022 | 91 | 0.200 |
Why?
|
False Positive Reactions | 10 | 2002 | 223 | 0.190 |
Why?
|
Phantoms, Imaging | 4 | 2013 | 448 | 0.190 |
Why?
|
United States | 5 | 2024 | 6989 | 0.190 |
Why?
|
Cluster Analysis | 5 | 2010 | 371 | 0.180 |
Why?
|
Electronic Health Records | 1 | 2024 | 347 | 0.180 |
Why?
|
Research Design | 2 | 2017 | 599 | 0.180 |
Why?
|
Case-Control Studies | 3 | 2016 | 1862 | 0.170 |
Why?
|
Contrast Media | 2 | 2016 | 1091 | 0.170 |
Why?
|
Software | 3 | 2013 | 665 | 0.160 |
Why?
|
Radiology | 4 | 2014 | 201 | 0.150 |
Why?
|
Retrospective Studies | 6 | 2023 | 9057 | 0.150 |
Why?
|
Models, Theoretical | 5 | 2010 | 491 | 0.150 |
Why?
|
Automation | 2 | 2018 | 111 | 0.150 |
Why?
|
Government Regulation | 1 | 2017 | 49 | 0.140 |
Why?
|
Likelihood Functions | 3 | 2010 | 251 | 0.140 |
Why?
|
Fourier Analysis | 3 | 2011 | 126 | 0.140 |
Why?
|
Radiography, Thoracic | 6 | 2002 | 322 | 0.140 |
Why?
|
Conflict of Interest | 1 | 2017 | 68 | 0.140 |
Why?
|
Bias | 1 | 2017 | 131 | 0.140 |
Why?
|
Equipment Failure Analysis | 2 | 2009 | 89 | 0.140 |
Why?
|
Area Under Curve | 3 | 2016 | 337 | 0.140 |
Why?
|
Time Factors | 2 | 2024 | 5338 | 0.130 |
Why?
|
Databases, Factual | 9 | 2018 | 856 | 0.120 |
Why?
|
X-Rays | 3 | 2013 | 135 | 0.120 |
Why?
|
Physicians | 1 | 2022 | 690 | 0.120 |
Why?
|
Middle Aged | 8 | 2024 | 25974 | 0.120 |
Why?
|
Iodine | 1 | 2012 | 43 | 0.110 |
Why?
|
Ovarian Cysts | 1 | 2012 | 17 | 0.100 |
Why?
|
Symporters | 1 | 2012 | 108 | 0.100 |
Why?
|
Biopsy | 3 | 2013 | 1184 | 0.100 |
Why?
|
Referral and Consultation | 1 | 2014 | 341 | 0.100 |
Why?
|
Diagnosis, Differential | 3 | 2013 | 1597 | 0.100 |
Why?
|
Nipples | 1 | 2011 | 37 | 0.100 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2012 | 48 | 0.100 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2012 | 62 | 0.100 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 306 | 0.100 |
Why?
|
Signal Processing, Computer-Assisted | 2 | 2010 | 202 | 0.100 |
Why?
|
Carcinoma, Endometrioid | 1 | 2012 | 49 | 0.100 |
Why?
|
Adult | 7 | 2024 | 26607 | 0.090 |
Why?
|
Quality Improvement | 1 | 2015 | 451 | 0.090 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 374 | 0.090 |
Why?
|
Aged | 5 | 2024 | 19165 | 0.090 |
Why?
|
Hemangioma | 1 | 2010 | 64 | 0.090 |
Why?
|
Photons | 1 | 2010 | 47 | 0.090 |
Why?
|
Tomography, X-Ray | 1 | 2009 | 18 | 0.090 |
Why?
|
Radionuclide Imaging | 2 | 2006 | 221 | 0.080 |
Why?
|
Clinical Competence | 1 | 2014 | 784 | 0.080 |
Why?
|
Computer Systems | 3 | 2000 | 79 | 0.080 |
Why?
|
Muscle, Skeletal | 1 | 2011 | 468 | 0.080 |
Why?
|
Logistic Models | 1 | 2012 | 1213 | 0.080 |
Why?
|
Equipment Design | 1 | 2009 | 417 | 0.070 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2008 | 63 | 0.070 |
Why?
|
Medical Oncology | 1 | 2011 | 383 | 0.070 |
Why?
|
Neuropilin-1 | 1 | 2007 | 14 | 0.070 |
Why?
|
Hepatocyte Growth Factor | 1 | 2007 | 85 | 0.070 |
Why?
|
Discrimination Learning | 1 | 2006 | 63 | 0.070 |
Why?
|
Data Interpretation, Statistical | 1 | 2007 | 299 | 0.060 |
Why?
|
Glioma | 1 | 2007 | 294 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 1 | 2016 | 3448 | 0.060 |
Why?
|
Evaluation Studies as Topic | 5 | 1998 | 270 | 0.060 |
Why?
|
Solitary Pulmonary Nodule | 2 | 2002 | 139 | 0.060 |
Why?
|
Liver Neoplasms | 1 | 2010 | 758 | 0.060 |
Why?
|
Absorptiometry, Photon | 1 | 2004 | 99 | 0.060 |
Why?
|
Evidence-Based Medicine | 1 | 2006 | 433 | 0.050 |
Why?
|
Bone Density | 1 | 2004 | 209 | 0.050 |
Why?
|
Medical Audit | 1 | 2022 | 39 | 0.050 |
Why?
|
Mathematics | 3 | 1995 | 191 | 0.050 |
Why?
|
Quality Assurance, Health Care | 1 | 2004 | 225 | 0.050 |
Why?
|
Feedback | 1 | 2022 | 134 | 0.050 |
Why?
|
Fuzzy Logic | 1 | 2000 | 15 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2006 | 1150 | 0.050 |
Why?
|
Neoplasms | 1 | 2015 | 3041 | 0.040 |
Why?
|
Biophysical Phenomena | 5 | 1998 | 124 | 0.040 |
Why?
|
Proof of Concept Study | 1 | 2018 | 48 | 0.040 |
Why?
|
Prognosis | 1 | 2006 | 3783 | 0.040 |
Why?
|
Angiography | 3 | 1995 | 208 | 0.040 |
Why?
|
Brain Neoplasms | 2 | 1996 | 782 | 0.040 |
Why?
|
Scattering, Radiation | 2 | 2013 | 116 | 0.040 |
Why?
|
Analysis of Variance | 2 | 2014 | 899 | 0.040 |
Why?
|
Pilot Projects | 2 | 2012 | 871 | 0.040 |
Why?
|
Discriminant Analysis | 1 | 2017 | 67 | 0.040 |
Why?
|
Population Surveillance | 1 | 2018 | 216 | 0.040 |
Why?
|
United States Food and Drug Administration | 1 | 2017 | 135 | 0.030 |
Why?
|
Eye | 1 | 1997 | 111 | 0.030 |
Why?
|
Signal Transduction | 1 | 2007 | 3385 | 0.030 |
Why?
|
Support Vector Machine | 1 | 2016 | 25 | 0.030 |
Why?
|
Adenomatous Polyposis Coli | 1 | 1996 | 39 | 0.030 |
Why?
|
Neoplasms, Multiple Primary | 1 | 1996 | 103 | 0.030 |
Why?
|
Attitude of Health Personnel | 1 | 2000 | 645 | 0.030 |
Why?
|
Copying Processes | 1 | 1994 | 6 | 0.030 |
Why?
|
Diffusion of Innovation | 1 | 2015 | 71 | 0.030 |
Why?
|
Radiography | 1 | 1996 | 809 | 0.030 |
Why?
|
Risk Factors | 2 | 2016 | 5499 | 0.030 |
Why?
|
Forecasting | 1 | 1995 | 306 | 0.030 |
Why?
|
Glioblastoma | 1 | 1996 | 265 | 0.030 |
Why?
|
Expert Systems | 1 | 1993 | 18 | 0.030 |
Why?
|
Georgia | 1 | 2012 | 35 | 0.030 |
Why?
|
Lung Neoplasms | 2 | 2002 | 2362 | 0.020 |
Why?
|
Lasers | 1 | 1992 | 107 | 0.020 |
Why?
|
Technology, Radiologic | 2 | 1998 | 104 | 0.020 |
Why?
|
Adipose Tissue | 1 | 2013 | 259 | 0.020 |
Why?
|
Optics and Photonics | 1 | 1989 | 27 | 0.020 |
Why?
|
Radiation Dosage | 2 | 1994 | 226 | 0.020 |
Why?
|
Quantum Theory | 1 | 1989 | 32 | 0.020 |
Why?
|
Health Physics | 1 | 1989 | 19 | 0.020 |
Why?
|
Luminescent Measurements | 1 | 1989 | 62 | 0.020 |
Why?
|
Prevalence | 1 | 2012 | 1243 | 0.020 |
Why?
|
Butadienes | 1 | 2007 | 34 | 0.020 |
Why?
|
Carcinoma, Ductal | 1 | 2007 | 18 | 0.020 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 123 | 0.020 |
Why?
|
Immunoblotting | 1 | 2007 | 273 | 0.020 |
Why?
|
Radiology Information Systems | 2 | 1999 | 79 | 0.020 |
Why?
|
Nitriles | 1 | 2007 | 160 | 0.020 |
Why?
|
Models, Structural | 1 | 1986 | 58 | 0.020 |
Why?
|
Carcinoma, Renal Cell | 1 | 1990 | 437 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2007 | 370 | 0.020 |
Why?
|
Tumor Burden | 1 | 2007 | 308 | 0.020 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2007 | 159 | 0.020 |
Why?
|
Neoplasms, Experimental | 1 | 2007 | 269 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2007 | 200 | 0.020 |
Why?
|
Transfection | 1 | 2007 | 911 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2007 | 557 | 0.020 |
Why?
|
Numerical Analysis, Computer-Assisted | 1 | 2004 | 33 | 0.020 |
Why?
|
Kidney Neoplasms | 1 | 1990 | 638 | 0.020 |
Why?
|
Neovascularization, Pathologic | 1 | 2007 | 364 | 0.020 |
Why?
|
Aged, 80 and over | 2 | 2012 | 6811 | 0.010 |
Why?
|
Database Management Systems | 1 | 2004 | 41 | 0.010 |
Why?
|
Computer Graphics | 1 | 2004 | 100 | 0.010 |
Why?
|
Phosphorylation | 1 | 2007 | 1132 | 0.010 |
Why?
|
Prospective Studies | 1 | 2012 | 4289 | 0.010 |
Why?
|
Radiometry | 1 | 2004 | 56 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2007 | 645 | 0.010 |
Why?
|
Decision Support Systems, Clinical | 1 | 2004 | 105 | 0.010 |
Why?
|
User-Computer Interface | 1 | 2004 | 187 | 0.010 |
Why?
|
Follow-Up Studies | 2 | 2001 | 3666 | 0.010 |
Why?
|
Disease Progression | 1 | 2007 | 1489 | 0.010 |
Why?
|
Methylmethacrylate | 2 | 1996 | 6 | 0.010 |
Why?
|
Methylmethacrylates | 2 | 1996 | 8 | 0.010 |
Why?
|
Cell Line | 1 | 2007 | 2496 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2007 | 1265 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2007 | 2558 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2007 | 1652 | 0.010 |
Why?
|
Fibrocystic Breast Disease | 1 | 1999 | 12 | 0.010 |
Why?
|
Fibroadenoma | 1 | 1999 | 9 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2005 | 1840 | 0.010 |
Why?
|
False Negative Reactions | 1 | 1998 | 63 | 0.010 |
Why?
|
Male | 4 | 2010 | 42411 | 0.010 |
Why?
|
Colloids | 1 | 1996 | 25 | 0.010 |
Why?
|
Lead | 1 | 1996 | 26 | 0.010 |
Why?
|
Age Distribution | 1 | 1996 | 200 | 0.010 |
Why?
|
Printing | 1 | 1994 | 4 | 0.010 |
Why?
|
Densitometry | 1 | 1994 | 29 | 0.010 |
Why?
|
Carcinoma, Transitional Cell | 1 | 1996 | 171 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 1995 | 360 | 0.010 |
Why?
|
Bone and Bones | 1 | 1995 | 269 | 0.010 |
Why?
|
Mice | 1 | 2007 | 11761 | 0.010 |
Why?
|
Stomach Neoplasms | 1 | 1996 | 282 | 0.010 |
Why?
|
Comorbidity | 1 | 1996 | 949 | 0.010 |
Why?
|
Coronary Angiography | 1 | 1993 | 242 | 0.010 |
Why?
|
Urinary Bladder Neoplasms | 1 | 1996 | 401 | 0.010 |
Why?
|
Pulmonary Fibrosis | 1 | 1993 | 137 | 0.010 |
Why?
|
Lung Diseases | 1 | 1993 | 269 | 0.010 |
Why?
|
Adenocarcinoma | 1 | 1996 | 1194 | 0.000 |
Why?
|
Animals | 1 | 2007 | 27371 | 0.000 |
Why?
|
Combined Modality Therapy | 1 | 1990 | 1719 | 0.000 |
Why?
|
Epoxy Resins | 1 | 1986 | 1 | 0.000 |
Why?
|
Survival Rate | 1 | 1990 | 1901 | 0.000 |
Why?
|
Computers | 1 | 1986 | 112 | 0.000 |
Why?
|
Quality Control | 1 | 1986 | 117 | 0.000 |
Why?
|
Brain | 1 | 1990 | 2285 | 0.000 |
Why?
|